Quick answer
iTind is a nitinol device that stays inside the prostatic urethra for about 5 to 7 days, presses at three points and is then removed, leaving nothing in the body.1,3 In the trial against a sham procedure, symptoms improved at 12 months, and no man developed new erectile or ejaculatory problems.6 The European guideline still lists the technique as under investigation.1 I assess iTind with each patient, together with Urolift, Rezum, Greenlight, HoLEP and EchoLaser.
What iTind is
iTind is made of nitinol, a flexible metal that returns to its original shape. It has three elongated struts and an anchoring leaflet.1 The urologist places the device through the urethra with a cystoscope and leaves it open inside the prostate, under direct vision. The struts press continuously on the wall of the urethra. At those points, the tissue undergoes a small area of necrosis from lack of blood flow and forms grooves, like shallow incisions, which leave the channel more open.1
In the MT-02 study, placement was done under light sedation, and all men went home the same day. The device was removed on average 5.9 days later, usually under topical anesthetic gel, as an outpatient procedure.3 After removal, nothing is left in the body.
Who the studies support it for
The European guideline places iTind among the non-ablative techniques still under investigation. It makes no recommendation and gives no prostate weight, and it says that trials comparing iTind with a reference technique are still ongoing.1
The MT-02 study included men with a prostate smaller than 75 g and excluded those with an obstructive middle lobe, a bleeding disorder or previous prostate surgery.3 In practice, this has to be assessed case by case. The choice takes into account the size and shape of the prostate, your symptoms, your medications and what you want to preserve.
What the studies show
| Study | Patients | Result |
|---|---|---|
| MT-02, 1 year | 81 men, 9 centers | IPSS 60% lower and flow 100% higher at 12 months3 |
| MT-02, 3 years | 50 men assessed | IPSS 58.2% lower and flow 114.7% higher; no late complications between 1 and 3 years4 |
| MT-02, over 4 years | 41 men assessed | IPSS 45.3% lower; retreatment in 4% after 3 years5 |
| Sham-controlled trial, 2021 | 175 men, 118 with iTind | At 12 months, IPSS 9.25 points lower and flow 3.52 mL/s higher6 |
The randomized trial assigned men 2 to 1 to iTind or to a sham procedure, in which only a catheter was placed and removed. No one knew their group until 3 months. At that point, 78.6% of men with iTind had a fall of at least 3 points in IPSS, against 60% in the sham group.6
MT-02 had no comparison group. In an analysis pooling several studies, cited by the European guideline, symptom improvement was smaller with iTind than with TURP.1 Relief tends to be smaller than with an operation that removes tissue, and that is part of the conversation before choosing.
Ejaculation and erections
In the sham-controlled trial, no man developed new ejaculatory or erectile problems.6 In the sexual function analysis of the same trial, erection scores did not change over 12 months, and men without erectile dysfunction at the start had better ejaculatory function.7 In MT-02, sexual function was stable for 3 years.4 In a review of 24 studies of minimally invasive treatments, loss of ejaculation was 1% with iTind.8 What changes with each technique is in ejaculation and erections after each technique.
Risks
In the randomized trial, 38.1% of men with iTind had an adverse event, against 17.5% in the sham group. Almost all were mild and temporary, grade I or II on the Clavien-Dindo scale.6 In MT-02, there were no complications above grade II.3 The European guideline cites, in a single-arm study, early complications in 12.5% of men, including urinary retention (3.1%), temporary leakage (3.1%) and infection (6.2%).1
After placement or removal, see a urologist if you have a fever, difficulty urinating or blood with clots.
How long it lasts and if another operation is needed
The European guideline cites retreatment in 5% at 3 years.1 In MT-02, two men had surgery between 3 and 4 years later, one TURP and one laser enucleation.5 In a review of 99 studies, retreatment was 11.1% at 4 years, and the authors warn that 65% of the studies had a high risk of manufacturer influence.9
When symptoms return, the first step is to find the cause. In a review by the endourology section of the European Association of Urology, repeating a minimally invasive treatment had not yet been reported after iTind, because studies are few, and traditional operations remain an option.10 What to look into is in symptoms back after prostate surgery.
What the guidelines say
- European guideline (EAU, 2026): lists iTind as a non-ablative technique under investigation, with no recommendation, pending trials against a reference technique.1
- American guideline (AUA, 2026): includes the temporary implanted device among the procedures for an enlarged prostate and says that shared decision-making with the patient is essential to choose the technique.2
Cost and health plans
I do not publish prices on the site, because the cost changes from one case to another: it depends on the hospital, the anesthesia, the device and what your plan authorizes. It is discussed individually, after the assessment. In my experience, Brazilian health plans have not authorized iTind.
| Part | What it is |
|---|---|
| Hospital | The operating room and the anesthesia for placement |
| Materials | The nitinol device, used once |
| Medical team | Placement and removal of the device |
The ANS, Brazil's health plan regulator, keeps the list of what Brazilian health plans are required to cover. In the current list, the prostate section includes TURP, laser photovaporization (the Greenlight technique), prostatectomy and other procedures, but no item under the name of iTind or of a temporary nitinol device.11 Each plan and contract has its own rules, so ask for authorization in advance and keep the answer in writing. If your plan says no, you can ask it to give the reason in writing.12 If you have insurance from outside Brazil, coverage depends on your policy, so ask your insurer before you travel.
How reimbursement works is in insurance and reimbursement, and the cost and coverage of every prostate operation is compared in prostate surgery cost.
iTind and the other techniques
iTind and Urolift do not remove tissue; the difference is that the Urolift implants stay in the body, while iTind comes out after a few days. Rezum uses water vapor, and the body absorbs the treated tissue. In a review, loss of ejaculation was 0% with Urolift, 1% with iTind and 3% with Rezum.8 I found no study comparing iTind directly with Rezum. HoLEP, Greenlight and TURP remove or vaporize the tissue, and retrograde ejaculation, in which semen goes into the bladder, is very common after them. EchoLaser treats the prostate with a laser through the perineum, without going through the urethra. The comparisons are in Rezum vs other minimally invasive treatments.
How I approach it
iTind is one of the options I assess with each patient, together with Urolift, Rezum, Greenlight, HoLEP, EchoLaser and TURP. Before recommending any technique, I look at the size and shape of the prostate, whether there is a middle lobe, your symptoms, your medications and what you want to preserve. I also explain that the European guideline still lists iTind as under investigation. We make the decision together.
I was one of the pioneers of Rezum in Brazil, performing some of the first procedures in the country in July 2023, and I have performed Greenlight since 2019, with more than 500 procedures. I am a proctor for both techniques and guide colleagues from other states through their first cases. The first consultation can be in person, at my office in Vila Mariana, or online, in English, with your tests sent in advance.
When to see a urologist
- If you have an enlarged prostate and medications do not bring enough relief
- If preserving ejaculation weighs on your decision
- If you want to know whether iTind suits your case
- If you have had iTind and your symptoms have come back
Send your case
If you would like to know, before a consultation, which technique makes sense for your prostate, fill in the form below. It goes to my office, and you will get a reply within 24 hours by email or WhatsApp. The form does not replace a consultation: it helps plan the next step.
Frequently asked questions
What is iTind?+
It is a device made of nitinol, a flexible metal, with three elongated struts and an anchoring leaflet. It is opened inside the prostatic urethra, presses at three points and stays for a few days. The pressure creates three grooves in the tissue, which leave the urinary channel more open. Then the device is removed, and nothing is left in the body.1,3
How long does iTind stay in?+
5 to 7 days. In the MT-02 study, it was removed on average 5.9 days after placement, usually under topical anesthetic gel.3
Who is iTind for?+
The European guideline still lists iTind as a technique under investigation and does not give a prostate weight.1 The main studies included prostates smaller than 75 g, with no obstructive middle lobe.3 In practice, this has to be assessed case by case.
Does iTind work?+
In the randomized trial against a sham procedure, with 175 men, the symptom score (IPSS) fell 9.25 points and flow increased 3.52 mL/s at 12 months.6 In MT-02, the improvement lasted 3 years.4 In an analysis pooling several studies, symptom improvement was smaller than with TURP.1
Does iTind preserve ejaculation?+
In the studies, yes. No man developed new erectile or ejaculatory problems in the sham-controlled trial or in MT-02.3,6 In a review of 24 studies, loss of ejaculation was 1%.8
What are the risks of iTind?+
In the randomized trial, 38.1% of men had an adverse event, almost always mild and temporary, against 17.5% in the sham group.6 The European guideline cites, in one study, urinary retention in 3.1%, temporary leakage in 3.1% and infection in 6.2%.1
How much does iTind cost? Do Brazilian health plans cover it?+
I do not publish prices, because the cost changes from one case to another. The current ANS list, which sets what Brazilian health plans must cover, has no item under the name of iTind or of a temporary nitinol device.11 In my experience, Brazilian health plans have not authorized iTind. Each plan and contract has its own rules, so ask for authorization in advance and keep the answer in writing. If you have insurance from outside Brazil, coverage depends on your policy.
Who can assess iTind for me in Brazil?+
I am Dr. Petronio Melo, a urologist and robotic surgeon in São Paulo, CRM-SP 157.598 and RQE 70.275. I was one of the pioneers of Rezum in Brazil and I am a proctor for Rezum and for Greenlight, which I have performed since 2019, with more than 500 procedures. In the consultation, I assess iTind alongside the other treatments for an enlarged prostate. My office is in Vila Mariana, and the first consultation can be in person or online, in English.
References
- EAU Guidelines on the Management of Non-neurogenic Male LUTS. European Association of Urology; 2026. Disease management chapter. EAU
- Goueli R, Badlani GH, Welliver C, et al. Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia: AUA Guideline (2026) Part III: Procedural/Surgical Management. J Urol. 2026;216(2):161-170. PubMed
- Porpiglia F, Fiori C, Amparore D, et al. Second-generation of temporary implantable nitinol device for the relief of lower urinary tract symptoms due to benign prostatic hyperplasia: results of a prospective, multicentre study at 1 year of follow-up. BJU Int. 2019;123(6):1061-1069. PubMed
- Amparore D, Fiori C, Valerio M, et al. 3-Year results following treatment with the second generation of the temporary implantable nitinol device in men with LUTS secondary to benign prostatic obstruction. Prostate Cancer Prostatic Dis. 2021;24(2):349-357. PubMed
- Amparore D, De Cillis S, Schulman C, et al. Temporary implantable nitinol device for benign prostatic hyperplasia-related lower urinary tract symptoms: over 48-month results. Minerva Urol Nephrol. 2023;75(6):743-751. PubMed
- Chughtai B, Elterman D, Shore N, et al. The iTind Temporarily Implanted Nitinol Device for the Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia: A Multicenter, Randomized, Controlled Trial. Urology. 2021;153:270-276. PubMed
- Elterman D, Alshak MN, Martinez Diaz S, et al. An Evaluation of Sexual Function in the Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia in Men Treated with the Temporarily Implanted Nitinol Device. J Endourol. 2023;37(1):74-79. PubMed
- Franco A, Ditonno F, Manfredi C, et al. Systematic Review and Pooled Analysis of Functional and Sexual Outcomes of Minimally Invasive Surgical Treatments for Benign Prostatic Obstruction. Eur Urol. 2026;89(4):318-331. PubMed
- Akgul B, Tozsin A, Aydın A, et al. Reintervention rates after minimally invasive benign prostatic hyperplasia therapies: a systematic review including industry involvement. World J Urol. 2025;43(1):494. PubMed
- Bogatova S, Morozov A, Gauhar V, et al. Management of clinical failure after minimally invasive surgical therapies (MIST) for BPH: repeat MIST versus resection, enucleation or ablation, a narrative review from EAU endourology. World J Urol. 2026;44(1):211. PubMed
- Agência Nacional de Saúde Suplementar (ANS). Rol de Procedimentos e Eventos em Saúde. Annex I of Normative Resolution No. 465/2021 and its amendments (version updated by RN No. 682/2026). ANS
- Agência Nacional de Saúde Suplementar (ANS). Justificativa de negativa de cobertura por escrito (written explanation of a coverage denial). ANS
Would you like to talk about your case?
In the consultation, I go over your tests and your priorities.
Book a consultation5.0186 Google reviews
